Paxlovid (nirmatrelvir/ritonavir) / Pfizer, China Meheco Group - LARVOL DELTA

Discovery of the SARS-CoV-2 Papain-Like Protease Inhibitor MR1-114: From Structure-Based Design to In Vivo Antiviral Efficacy. (PubMed, J Med Chem) - "Notably, the compound exhibits preferential lung enrichment in mice and rats while maintaining broad-spectrum activity against variants, including Delta and Omicron BA.5 with nanomolar potency in vitro. In the K18-hACE2 mouse model, oral administration of MR1-114 matched the therapeutic efficacy of nirmatrelvir, significantly suppressing pulmonary viral replication and preventing disease-associated weight loss."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Systems Immunology of Long Covid: Insights from the STOP-PASC Clinical Trial (IMMUNOLOGY 2026) - "Despite proposed viral persistence mechanisms, no therapeutic benefit was observed in randomized placebo-controlled trials of nirmatrelvir/ritonavir (NMV/r) in adults with Long COVID, including the Selective Trial of Paxlovid for PASC (STOP-PASC)... These findings advance our understanding of Long COVID immunology and may help direct future proteomic biomarker endpoints for Long COVID clinical trials."

Clinical • Cardiovascular • Epstein-Barr Virus Infections • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COLD AGGLUTININ SYNDROME FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (EBMT 2026) - "GVHD prophylaxis included Thymoglobuli"

Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Transplantation • CD4 • CD8 • HP

COLD AGGLUTININ SYNDROME FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (EBMT 2026) - "GVHD prophylaxis included Thymoglobuli"

Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Transplantation • CD4 • CD8 • HP

Paxlovid shows organ-specific and age-specific impacts on risk of developing post-acute sequelae of COVID-19. (PubMed, Commun Med (Lond)) - "Paxlovid demonstrates organ-specific effects on the risk of PASC, with a reduction in gastrointestinal symptoms and an increased risk of eye and ear-related symptoms. In older, non-hospitalized patients, Paxlovid modestly reduces overall PASC risk. These findings highlight the complexity of antiviral therapy's long-term impact and underscore the need for further research to clarify the mechanisms underlying these outcomes."

Journal • Infectious Disease • Novel Coronavirus Disease

Inhibitory potential of Morus alba leaf extract and its phytoconstituent against SARS-CoV-2 main protease: An integrative in silico and in vitro analysis. (PubMed, J Mol Graph Model) - "Naringin, nicotiflorin, and cyclomorusin emerged as top hits with binding affinities ranging from -9.8 to -9.6 kcal/mol, compared to the reference drug, i.e., nirmatrelvir (-9.0 kcal/mol)...In conclusion, these findings suggest that MA extract notably downregulated the transient expression of the main protease in CHO cells, and computational analysis identifies naringin as a potential allosteric inhibitor. However, further investigations are required to confirm direct enzyme-inhibition activity and viral infection studies for future drug development."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Severe COVID-19 in the Republic of Korea: Epidemiology, Risk Factors, Therapeutics, and Prognostic Models From Nationwide Data. (PubMed, J Korean Med Sci) - "Antiviral therapies, notably nirmatrelvir/ritonavir and molnupiravir, significantly reduced severe outcomes, while immunomodulators such as dexamethasone and tocilizumab improved recovery in patients with severe disease. The rapid generation of evidence on predicting, preventing, and treating severe disease is a critical element of pandemic preparedness. Although COVID-19 has transitioned to an endemic disease, sustaining and advancing the research expertise and infrastructure developed during the pandemic remains essential for responding to future emerging infectious disease outbreaks."

Journal • Review • Asthma • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Diabetes • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Mental Retardation • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Obesity • Oncology • Psychiatry • Pulmonary Disease • Renal Disease • Respiratory Diseases • Solid Organ Transplantation • Transplantation

Based a machine learning approach to investigate the factors influencing nirmatrelvir/ritonavir exposure in human plasma: a multicenter, observational study. (PubMed, Front Cell Infect Microbiol) - "We identified a set of variables that affect the treatment of N/R through therapeutic drug monitoring and established a machine learning model capable of predicting N/R concentrations with satisfactory performance. These findings provide a basis for integrating TDM with multivariable prediction tools to personalize N/R dosing and improve medication safety."

Journal • Observational data • Retrospective data • Infectious Disease • Novel Coronavirus Disease

IS20 - Not just another respiratory disease: how can we stop the reverberations of COVID-19? (ESCMID Global 2026) - "Organised by Pfizer Motivate infectious disease specialists to see through the cloud of apathy and look differently at COVID-19; ensuring that every eligible patient receives the treatment they deserve to protect their future health. Message Focus: - Mechanism of disease and role of the ACE2r, including its multisystemic impact on multiple organ systems - Impact of COVID-19 in the short-, mid- and long-term (ongoing symptoms, exacerbation of existing conditions, and new-onset conditions) - Identifying eligible patient populations (e.g., those with comorbidities) for treatment with PAXLOVID - Clinical data and an evolving body of RWE suggests that timely acute treatment with PAXLOVID can have long-term benefits"

Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Emerging insights: contemporary data on COVID-19 and Nirmatrelvir-Ritonavir (ESCMID Global 2026) - "Organised by Pfizer"

Infectious Disease • Novel Coronavirus Disease

IPT25 - Emerging insights: contemporary data on COVID-19 and Nirmatrelvir-Ritonavir (ESCMID Global 2026) - "Organised by Pfizer"

Infectious Disease • Novel Coronavirus Disease

Implications of enhanced outpatient use of oral nirmatrelvir/ritonavir for COVID-19: insights from the perspective of the Spanish National Health System (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease • Novel Coronavirus Disease

Evaluating drug interaction risks of nirmatrelvir and ritonavir combination (Paxlovid®) and remdesivir with concomitant medications in real-world clinical settings in an upper-middle-income country (ESCMID Global 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Infectious Disease • Novel Coronavirus Disease

Association of nirmatrelvir/ritonavir treatment with mortality among elderly patients with healthcare-associated COVID-19 (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease • Novel Coronavirus Disease

Baseline risk of hospitalisation and death in a nirmatrelvir/ritonavir treatment-eligible population with mild-to-moderate COVID-19: a systematic literature review (ESCMID Global 2026) - No abstract available

Clinical • Review • Infectious Disease • Novel Coronavirus Disease

Effectiveness of nirmatrelvir/ritonavir in preventing severe COVID-19 outcomes: national multi-year real-world data from Greece (ESCMID Global 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Infectious Disease • Novel Coronavirus Disease

A retrospective study on nirmatrelvir/ritonavir and azvudine in treating COVID-19 in patients with cirrhosis (APASL 2026) - No abstract available

Retrospective data • Fibrosis • Hepatology • Immunology • Infectious Disease • Novel Coronavirus Disease

Effectiveness of nirmatrelvir/ritonavir and molnupiravir on post-COVID diabetes risk among an older adult cohort: a target trial emulation study. (PubMed, BMC Med) - "Our study demonstrates the effectiveness of nirmatrelvir/ritonavir in reducing the risks of post-acute COVID sequelae of diabetes in the hospitalized population, regardless of their diabetic status, whereas molnupiravir showed no significant benefit. Our findings offer valuable clinical insights for managing diabetes during the post-acute phase of SARS-CoV-2 infection."

Journal • Diabetes • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Respiratory Diseases

Tacrolimus toxicity precipitated by Paxlovid in a renal transplant recipient: a case report of drug–drug interaction and system-level failures (UKKW 2026) - "Next step National pharmacovigilance and mandatory electronic prescribing hard-stops with transplant-specific interaction flags should be embedded across UK discharge systems. Centre-level audit of Paxlovid prescribing in immunosuppressed patients will be essential to track outcomes and eliminate recurrence."

Case report • Clinical • Diabetes • Glomerulonephritis • IgA Nephropathy • Infectious Disease • Nephrology • Novel Coronavirus Disease • Renal Disease • Transplantation

The JN.1 Variant: Emergence and Global Spread. (PubMed, Curr Pharm Des) - "Antiviral medications such as Lagevrio, Veklury, and Paxlovid also remain effective against JN.1. Continuous surveillance approaches, including digital tracking systems, wastewater monitoring, and genomic sequencing, are essential for the early detection and control of JN.1."

Journal • Cough • Infectious Disease • Novel Coronavirus Disease • Otorhinolaryngology • Respiratory Diseases

Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID-19 and Severe Renal Impairment. (PubMed, Clin Pharmacol Ther) - P1 | "Findings suggest that the studied regimen is well tolerated, achieves and maintains adequate exposure, and is suitable for patients with COVID-19 and severe renal impairment. NCT05487040."

Journal • PK/PD data • Infectious Disease • Novel Coronavirus Disease • Renal Disease • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=10000 | Recruiting | Sponsor: UMC Utrecht | Phase classification: P4 ➔ P3 | N=7100 ➔ 10000 | Trial completion date: Dec 2023 ➔ Dec 2025 | Trial primary completion date: Dec 2021 ➔ Dec 2023

Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=6800 | Recruiting | Sponsor: MJM Bonten | N=4000 ➔ 6800 | Trial completion date: Feb 2019 ➔ Jun 2022 | Trial primary completion date: Feb 2019 ➔ Dec 2021 | Initiation date: Dec 2015 ➔ Apr 2016

Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=7100 | Recruiting | Sponsor: MJM Bonten | Trial completion date: Jun 2022 ➔ Dec 2023

Trial completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=4000 | Recruiting | Sponsor: UMC Utrecht

New P4 trial • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases